Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie's agreement to pay up to $2.1 billion for Capstan Therapeutics signals that Big Pharma sees in vivo CAR-T, delivered through engineered lipid…
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout's…
AbbVie announced today that it has completed its acquisition of Capstan Therapeutics. Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
AbbVie agreed to acquire Capstan Therapeutics for up to $2.1B in cash. Gains CPTX2309 (Phase 1 in vivo anti-CD19 CAR-T for B-cell autoimmune diseases) and Capstan's proprietary tLNP platform for RNA delivery enabling in vivo cell engineering. Completed August 19, 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Capstan Therapeutics, Inc. (this deal) | 2025 | $2.1B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2025 deals · AbbVie Inc. deals · Immunology deals